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PSCIENCE ADVISORY
Percutaneous Device Closure of Patent Foramen
Ovale for Secondary Stroke Prevention
A Call for Completion of Randomized Clinical Trials
A Science Advisory From the American Heart Association/American Stroke Association
and the American College of Cardiology Foundation
The American Academy of Neurology affirms the value of this science advisory.
Patrick T. O’Gara, MD, FAHA, FACC, Chair; Steven R. Messe, MD, FAHA;
E. Murat Tuzcu, MD, FAHA, FACC; Gloria Catha, BA; John C. Ring, MD, FACC
bstract—The optimal therapy for prevention of recurrent stroke or transient ischemic attack in patients with cryptogenic stroke and patent
oramen ovale has not been defined. Although numerous observational studies have suggested a strong association between patent foramen
vale and cryptogenic stroke, a causal relationship has not been convincingly established for the majority of affected patients. Treatment choices
nclude medical therapy with antiplatelet agents or vitamin K antagonists, percutaneous device closure, or open surgical repair. Whereas suture
losure of an incidental patent foramen ovale is performed routinely during the course of an operation undertaken for another indication, primary
urgical repair is rarely advocated in the current era. The choice between medical therapy and percutaneous device closure has been the subject
f intense debate over the past several years, albeit one that has not been adequately informed by randomized, prospective clinical trial data to
ermit an objective comparison of the relative safety and efficacy of these respective approaches. Enrollment in clinical trials has lagged
onsiderably despite frequent calls for participation from the US Food and Drug Administration and major professional societies. Completion and
eer review of ongoing trials are critical steps to establish an evidence base from which clinicians canmake informed decisions regarding the best
herapy for individual patients. The present advisory strongly encourages all clinicians involved in the care of appropriate patients with cryptogenic
troke and patent foramen ovale—cardiologists, neurologists, internists, radiologists, and surgeons—to consider referral for enrollment in these
andmark trials to expedite their completion and help resolve the uncertainty regarding optimal care for this condition (J Am Coll Cardiol
ublished by Elsevier Inc. doi: 10.1016/j.jaac.2009.04.001009;53:2014–8)
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atroke is the third-leading cause of death among adults in
the United States and a major contributor to long-term
unctional impairment and disability (1). Despite recent
dvances in diagnosis and treatment, approximately one fifth
f stroke survivors require institutional care 3 months after
he index event, and 15% to 30% are permanently disabled (1).
ggressive measures of primary prevention for at-risk pa-
ients are critical, because the majority of strokes are first
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ermission of the American College of Cardiology Foundation. Please contactvents (2). Nevertheless, of the estimated 780 000 strokes that
ccur in the United States each year, 180 000 are recurrent
vents (1). Secondary prevention is equally important for
urvivors of stroke or transient ischemic attack (3). The
0-day risk of stroke after transient ischemic attack has been
stimated at 3% to 17% and is highest within the first 30
ays (1). The incidence of stroke appears to be increasing,
nd the associated economic costs are staggering. The 2008
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May 26, 2009:2014–8 Percutaneous Device Closure for Stroke Preventiontimated direct and indirect cost of stroke is $65.5 billion,
ith a mean per capita lifetime cost of $140 048 (1). The
ajority of strokes are ischemic; of these, approximately 25%
40% have no identifiable cause despite a thorough evalu-
ion and are designated as cryptogenic stroke (CS) (4–7).
ther causes of ischemic stroke include large-artery athero-
lerotic infarction, cardiac embolism, small-vessel disease,
a defined abnormality such as arterial dissection, hyperco-
ulable state, or sickle cell disease.
A patent foramen ovale (PFO) is a remnant of the fetal
rculation and has been identified at autopsy in 27% of
tients with normal hearts (8). In that postmortem series, its
evalence appeared to decline with age. Using contrast
ansthoracic echocardiography, Di Tullio and colleagues (9)
tected a PFO in 14.9% of 1100 stroke-free subjects older
an 39 years of age. An atrial septal aneurysm was present in
5% of the total patient cohort, most often in association
ith PFO. Meissner et al. (10), using transesophageal echo-
rdiography, reported a higher 24.3% prevalence rate
ong 585 randomly sampled Olmsted County, Minne-
ta, residents 45 years of age or older participating in the
troke Prevention Assessment of Risk in a Community
PARC) study. An atrial septal aneurysm was present in
9% of subjects, including 4.3% of those with PFOs. The
agnosis of PFO is established by demonstration of an
teratrial communication with right-to-left transit of con-
ast microbubbles within 3 to 4 cardiac cycles of right
rial opacification (11). An atrial septal aneurysm is
fined as a redundant and hypermobile portion of the
teratrial septum that demonstrates more than 10-mm
cursion from the centerline during the cardiac cycle (12).
PFO provides an anatomic substrate for paradoxical
bolization of thrombus with CS, as convincingly dem-
strated in isolated echocardiographic case reports (13).
most case series, deep venous thrombosis and/or
rombus-in-transit has been identified in only a small
inority of patients with PFO and CS, although thrombo-
s prevalence rates may vary as a function of the screening
ethods used for detection (14 –16). Other potential mech-
isms of CS among patients with PFO include paroxys-
al atrial fibrillation (which may not bear any relation to
e PFO itself), formation and release of thrombus from
e rim of the defect or the left atrial aspect of an
sociated atrial septal aneurysm, the passage of unmea-
red vasoactive humoral substances that escape pulmo-
ry degradation, and causes not related to the defect (17).
Most but not all observational studies have reported a
gher prevalence of PFO among patients with CS than
ong normal control subjects and/or among patients for
hom a cause of stroke could be identified. The association
tween PFO and CS has been more convincingly demon-
rated for younger (less than 55 years of age) versus older
5 years of age or older) patients. For example, Lamy et al. (18)
tected a PFO with transesophageal echocardiography in
.9% of 581 young CS patients. In the Patent Foramen
vale in Cryptogenic Stroke Study (PICSS), a PFO was
esent by transesophageal echocardiography criteria in de.8% of patients 30 to 85 years of age (19). PFO was found
39.2% of CS patients versus 29.9% of patients with a
own cause of stroke (p0.02). Handke and colleagues (20)
ve recently reported a statistical association between PFO
d CS for both younger and older (greater than 55 years of
e) patients. In their study, the prevalence of PFO was
.9% among younger CS patients compared with 14.3%
ong younger patients with stroke of known cause (odds
tio 4.70, 95% confidence interval [CI] 1.89 to 11.68,
0.001) and 28.3% among older CS patients compared with
.9% among older patients with stroke of known cause
dds ratio 2.92, 95% CI 1.70 to 5.01, p0.001) (20).
evalence rates of PFO among patients with CS do not
uate with the longitudinal risk of stroke among asymptom-
ic subjects with PFO. In the Northern Manhattan Study
OMAS), PFO was not associated with increased stroke risk
a multiethnic cohort of both men and women or in patients
unger or older than 60 years (9). PFO was also not a
gnificant, independent predictor of stroke among normal
bjects older than 45 years of age in the Olmsted County
ARC study (10). Although many studies have implicated
increased risk of stroke related to the anatomic size of the
O, the magnitude of the right-to-left shunt, and the coex-
tence of an atrial septal aneurysm, these associations have
t been observed consistently (3,16,21,22).
A PFO is usually detected as part of an evaluation for a
rdioembolic source of stroke. Estimates of annual rates of
current stroke among patients with PFO range from 1.5% to
% and depend on the characteristics of the population
udied, including age (3,23). In the Lausanne study (24), in
hich patients were treated with aspirin, anticoagulation, or
O closure, the annual stroke rate was 1.9%. In PICSS,
hich included patients older than those in the Lausanne
udy, all subjects were treated with aspirin (325 mg daily) or
arfarin anticoagulation (international normalized ratio 1.4 to
8, mean 2.040.99). The 2-year primary event rate for
l-cause death or recurrent ischemic stroke was 15.9% (19).
here was no significant difference in primary event rates
tween patients with versus those without PFO. Whereas
ujec et al. (25) reported that warfarin may be more effective
an antiplatelet therapy for secondary stroke prevention, in
CSS, the primary event rates for CS patients with PFO
eated with warfarin (n42) were not significantly different
om those of patients treated with aspirin (n56; 9.5%
rsus 17.9%, hazard ratio 0.52, 95% CI 0.16 to 1.67,
0.28), although the study was not adequately powered for
is specific comparison and the mean international normal-
ed ratio achieved was 2.04 (19). In addition, event rates
ere similar for CS patients without PFO treated with
arfarin (n72, 8.3%) or aspirin (n80, 16.3%; hazard ratio
50, 95% CI 0.19 to 1.31, p0.16) (19). A systematic review
nonrandomized studies of transcatheter closure (n10) or
edical therapy (n6) for PFO reported a 1-year rate of
current neurological thromboembolism of 0% to 4.9% with
anscatheter intervention and 3.8% to 12.0% with medical
erapy (26). Rates of major and minor complications with
vice closure were 1.5% and 7.9%, respectively. Wöhrle’s
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Percutaneous Device Closure for Stroke Prevention May 26, 2009:2014–8ore recent review of nonrandomized trials has also sug-
sted a lower rate of recurrent stroke after device closure of
O, especially among patients with coexistent atrial septal
eurysm (22). The mean frequency of major complications
as 2.3% among patients undergoing PFO closure.
Both the American Heart Association/American Stroke
ssociation (AHA/ASA) (3) and American College of Chest
ysicians (ACCP) (27) guidelines recommend antiplatelet
erapy for patients with ischemic stroke or transient ische-
ic attack and PFO (AHA/ASA Class IIa, level of evidence:
; ACCP grade 1A), unless other indications exist for vitamin
antagonist therapy (e.g., atrial fibrillation, hypercoagulable
ate; AHA/ASA Class IIa, Level of Evidence: C; ACCP
ade 1C). The AHA/ASA guidelines for secondary stroke
evention state that “insufficient data exist to make a
commendation about PFO closure in patients with a first
roke and a PFO. PFO closure may be considered for patients
ith recurrent CS despite optimal medical therapy (Class IIb,
evel of Evidence: C)” (3).
No device specific for PFO closure after CS has been
proved by the US Food and Drug Administration
DA) (28 –30). Three FDA advisory committee meetings
997, 2002, and 2007) over the past 10 years have
firmed the need for completion of appropriately powered
ndomized, controlled clinical trials to compare medical
erapy with percutaneous device closure. Enrollment in
ials has been insufficient to allow completion and has
gged considerably for several reasons, including the
rongly held opinions of individual clinicians, investiga-
ble. Current Ongoing Clinical Trials on PFO Closure to Prevent
ial Name Device Utilized Sponsor St
SPECT: Randomized
aluation of Recurrent
roke Comparing PFO
osure to Established
rrent Standard of Care
eatment
Amplatzer PFO occluder AGA Medical
OSURE-I: Evaluation of
e STARFlex® Septal
osure System in Patients
ith a Stroke or TIA Due to
e Possible Passage of a
ot of Unknown Origin
rough a Patent Foramen
ale (PFO)
STARFlex® septal
closure system
NMT Medical
-Trial: Patent Foramen
ale and Cryptogenic
bolism
Amplatzer PFO occluder AGA Medical
tent Foramen Ovale
osure or Anticoagulants
rsus Antiplatelet Therapy
Prevent Stroke
currence (CLOSE)
Any device can be used
provided it has been
approved by the ad hoc
committee of the study
Assistance
Publique–Hopitaux
de Paris
RE HELEX™ Septal
cluder for Patent
ramen Ovale (PFO)
osure in Stroke Patients
ore REDUCE)
GORE HELEX™ septal
occluder
WL Gore and
Associatesrs, and patients regarding optimal therapy for recurrent Paroke prevention in a predominantly younger population,
ncerns regarding the limitations and pitfalls of medical
erapy, the reluctance of patients and physicians to
rticipate in randomized treatment trials, and the wide-
read off-label use of closure devices. Indeed, Opotowsky
al. (31) reported a 50-fold increase in the weighted
tional estimate of the annual number of percutaneous
FO/atrial septal defect closures over the time period of
98 to 2004. After FDA review, the human device
emptions for 2 percutaneous closure devices granted in
00 and 2002 were withdrawn in 2006, because the
tient population described by the approved indication
atients with recurrent CS due to presumed paradoxical
bolism through a PFO for whom conventional drug
erapy has failed) was significantly in excess of 4000
tients per year in the United States (32). This finding
eant that these devices were no longer eligible for
manitarian use device designation and therefore could
t be marketed under a human device exemption. Inves-
gational device exemption studies are available to permit
igible patients access to these devices. Three such trials
e ongoing in the United States (RESPECT [Randomized
valuation of recurrent Stroke comparing PFO closure to
stablished Current standard of care Treatment] [33], CLO-
RE I [Evaluation of the STARFlex® Septal Closure
ystem in Patients With a Stroke or Transient Ischemic
ttack due to Presumed Paradoxical Embolism through a
O] [34], and REDUCE [GORE HELEX™ Septal Oc-
uder for Patent Foramen Ovale (PFO) Closure in Stroke
rent Cryptogenic Stroke
Projected Completion
Date
Estimated
Enrollment For More Information
Study ongoing;
completion date not
available
500 http://www.strokecenter.org/trials
Study ongoing; no longer
recruiting participants
900 http://www.clinicaltrials.gov
Identifier # NCT00201461
Study ongoing; projected
to complete in December
2007 but has been
extended
500 http://www.clinicaltrials.gov
Identifier # NCT00166257
December 2012 900 http://www.clinicaltrials.gov
Identifier # NCT00562289
2014 664 http://www.clinicaltrials.gov
Identifier # NCT00738894Recur
art Date
2003
2003
2000
2007
2008tients (Gore REDUCE)] [35]), 1 in France (Patent Foramen
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May 26, 2009:2014–8 Percutaneous Device Closure for Stroke Preventionvale Closure or Anticoagulants versus Antiplatelet Therapy
Prevent Stroke Recurrence [CLOSE]) (36), and 1 in
urope and Australia (PC-Trial) (37). The current status of
ese ongoing trials is summarized in the Table. At its most
cent meeting, the FDA’s Circulatory System Devices Panel
ked for the support of provider and voluntary health
ganizations to increase awareness regarding the need to
mplete these trials (38). The importance of patient and
ovider education was emphasized. Recommendations were
sued to facilitate statistically appropriate pooling of data
ross trials when possible and to curtail the off-label use of
osure devices.
The magnitude of the problem posed by recurrent stroke
patients with CS and PFO, coupled with the continued
certainty regarding the optimal approach to secondary
evention, underscores the critical need for completion of
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